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A B S T R A C T
Objective: Most cases of sudden unexpected death in epilepsy (SUDEP) follow a seizure, and most deaths
occur while people are in bed, presumably sleeping. Nocturnal seizures are reported to be a risk factor
for SUDEP. People with nocturnal frontal lobe epilepsy (NFLE) have seizures predominantly or exclu-
sively during sleep, oftenmany times per night. The present study aimed to assess whether NFLE represents
a high-risk condition for SUDEP.
Methods: The present study retrospectively assessed the incidence of SUDEP in a cohort reconstructed
from a dedicated database of consecutive patients referred to the Epilepsy and Sleep Centres of the In-
stitute of Neurological Sciences of Bologna from 1980 to 2012 with: (1) a diagnosis of NFLE, (2) at least
90% of seizures during sleep, and (3) at least one-year of follow-up.
Results: One hundred and three people were included. The median time from seizure onset to last ob-
servation was 26 years, equal to a follow-up of 2789 person-years. One person died of SUDEP during
the follow-up period. The incidence rate of SUDEP was 0.36 per 1000 person-years (95% CI 0.01 to 2.0).
Conclusions: The incidence of SUDEP in the participant population was not higher than the rates
previously reported in prevalent epilepsy populations (0.4 to 2.3 per 1000 person-years). The low
prevalence of SUDEP might reﬂect the low occurrence of generalised tonic-clonic seizures in people with
NFLE.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The pathogenicmechanisms underlying sudden unexpected death
in epilepsy (SUDEP) have not yet been unravelled. However, epide-
miological studies have pointed to a number of risk factors and
precipitating situational circumstances. A terminal seizure appears to
be almost universal in the witnessed episodes and when the circum-
stances of death are reliably recreated [1–8]. Being found dead in bed
is very common, especially in a prone position, presumably meaning
that deaths occur preferentially during sleep, and the vast majority of
the SUDEP cases recorded in video electroencephalography (EEG)moni-
toring units occurred at night [1,4–10]. Accordingly, a recent study
suggested that a history of nocturnal seizures might be an indepen-
dent risk factor for SUDEP [10].
Nocturnal frontal lobe epilepsy (NFLE) is a syndrome in which
seizures occur mostly or exclusively during sleep and tend to be very
frequent, occurring up to dozens of times per night [11]. Based on
these assumptions, people with NFLE might be at higher risk of
SUDEP. The aim of the present study was to assess the incidence
of SUDEP retrospectively in a cohort of patients with NFLE, strict-
ly deﬁned as having more than 90% of seizures during sleep.
2. Methods
The present research is reported following the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) guide-
lines [12]. This retrospective cohort study was part of a larger study
designed by the Istituto di Ricovero e Cura a Carattere Scientiﬁco
(IRCCS) of Neurological Sciences (INS) Bologna to investigate the
features of NFLE. After approval by the local ethical (cod. 13084)
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committee, the study was conducted from November 2012 to
December 2013.
2.1. Data sources
All patients attending the Epilepsy and Sleep Centres of the In-
stitute of Neurological Sciences of Bologna between 1980 and
September 2012 for paroxysmal sleep-related events compatible with
frontal lobe seizures were progressively screened. The initial pool
was partly reconstructed retrospectively by collecting historical,
medical and video-polysomnographic (VPSG) records from the da-
tabase of the Institute. A medical chart recording clinical and
instrumental updates at every control visit or telephone/e-mail
contact was available for each patient. Control visits in the centres
were scheduled on an individual patient basis, depending on clin-
ical needs, with intervals generally ranging from 6 to 12 months.
2.2. Cohort identiﬁcation and data collection
Patients were eligible if they were diagnosed with NFLE, accord-
ing to the following criteria: (1) apersonal historyofmotor events arising
predominantly from sleep, suggestive of a primary or secondary in-
volvement of frontal lobe structures; (2) video-polysomnographic
recording of one hyperkinetic/asymmetric tonic-dystonic episode or at
least two stereotyped paroxysmal arousals (PA) [11,13].
Three experts in sleepmedicine and epileptology (PT, FP, FB) con-
ﬁrmed the ﬁnal diagnosis. All cases with VPSG recordings of
stereotyped PA that were not associated withmajor ictal events were
carefully reviewed and discussed collegially; the follow-up data were
also considered, when available. The agreement required for the ﬁnal
diagnosis was 100%; otherwise these cases were considered doubt-
ful and not included in the study.
Further inclusion criteria were: ≥90% of seizures occurring during
sleep and within at least one year of follow-up. The lifetime rate
of sleep seizures was independently assessed by BM and LD on the
basis of the clinical records; doubtful cases were discussed and cases
were only included when there was agreement. All data were ret-
rospectively reviewed until last contact or death. Every effort was
made to contact all of the patients who had their last visit prior to
2012 for a telephone interview aimed at verifying their current status
and to update clinical information.
2.3. Terminology
Deﬁnite, probable and possible cases of SUDEP and SUDEP Plus
were deﬁned according to Nashef et al. [14].
2.4. Statistical analysis
The incidence of SUDEP was derived from the total number of
people with SUDEP and the total person-year follow-up for thewhole
cohort. The 95% conﬁdence interval (95% CI) was calculated ac-
cording to the Poisson distribution.
3. Results
3.1. Population characteristics
In October 2013, the NFLE database contained 165 people. After
reviewing the medical charts, 103 were judged to be eligible and
included in the study (Fig. 1).
The median time from seizure onset to last observation was 26
years (range 2 to 81 years; mean 27 years; 25th percentile 18 years;
75th percentile 33 years), equal to a follow-up of 2789 person-
years, counted from epilepsy onset to last observation/death. Among
the people who did not have a check-up in the previous two years,
13 could not be reached by telephone due to a change in number,
so their last contact preceded 2012. The median time since seizure
onset to last observation in this subgroup was 23 years (range 10
to 39 years).
The study cohort comprised 70 males and 33 females. The mean
age at onset of epilepsy was 15 years (range 0 to 53). The mean age
at last observation was 43 years (range 9 to 86).
The maximum lifetime frequency of seizures was every night for
80 people (77.7%), weekly for 17 (16.5%), monthly for three (2.9%),
sporadic for one (1.0%) and unknown for two (1.9%). Frequency of
seizures is represented in Fig. 2, as it was at onset (A), at their peak
(B) and at last observation (C).
Twenty-nine people (28.1%) experienced secondary generalised
tonic-clonic seizures (GTCS). This kind of seizure presented as a unique
event or had a sporadic lifetime frequency in 17 people (16.5%), had
a maximum lifetime frequency of one or more per year in six people
(5.8%), a monthly maximum lifetime frequency in one person (1%),
and an unknown maximum frequency in ﬁve people (4.8%).
Eight people (7.8%) had obstructive sleep apnoea (OSA), which
was considered moderate-to-severe and required continued posi-
tive airway pressure (CPAP) treatment in four of them. In the
remaining four, OSA was considered to be mild and a weight-loss
programme was undertaken.
Eight people (7.8%) refused antiepileptic medication; 39 (37.8%)
had been on monotherapy and 56 (54.4%) on polytherapy at some
time during their lives. As a ﬁrst line treatment, they were gener-
ally offered carbamazepine once a day, at night. Carbamazepine,
alone or in combination, had been taken by 88 people (85.4%).
Lamotrigine, alone or in combination, had been taken by 16 people
(15.5%).
Ten people (9.7%) underwent a pre-surgical work-up: two sub-
sequently underwent surgery (one removal of a left frontal Taylor
dysplasia and the other a frontal corticectomy for an architectural
dysplasia), three were judged to be inoperable after the pre-
surgical work-up, three refused to undergo surgery or stereo-EEG,
one improved signiﬁcantly with the pharmacological therapy, and
in one, the intervention was not performed due to signiﬁcant sur-
gical risk (see case description below).
A table listing the main characteristics of the people who were
excluded because of <90% seizures during sleep is available as a sup-
plementary ﬁle (Table 1).
3.2. Mortality rate and incidence of SUDEP
Two people died during the follow-up period. The mortality rate
was 0.72 per 1000 person-years (95% CI 0.09 to 2.6). For one, the
diagnosis was probable SUDEP (see SUDEP case description below).
Fig. 1. Flow diagram of the patients with NFLE.
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According to the newly proposed criteria [14], the diagnosis was
reformulated into ‘Probable SUDEP Plus’. The other person (32 years
old) died in a boat accident, in which there were witnesses: a ter-
minal seizure and sudden death were reasonably excluded.
The incidence rate of SUDEPwas 0.36 per 1000 person-years (95%
CI 0.01 to 2.0).
3.3. SUDEP case description
The person was a 43-year-old man. His family history was un-
remarkable for epilepsy and sudden death; his father had chronic
ischaemic heart disease. The man had severe OSA and was about
to start CPAP therapy. He had an IQ of 71 and suffered from stut-
tering. His epilepsy started at the age of three. Seizures were
characterised by right cephalic tingling or whistling in his right ear,
subsequent tonic posturing of the right arm, right head turning, right
eyelid myoclonus, sialorrhoea, and subsequent possible asymmet-
ric tonic posturing of the inferior right limb and left arm. He could
be conscious, but was unable to speak throughout the episode. The
longest episodes tended to end with apnoea and myoclonus of all
four limbs.
Since the age of 16, seizures had occurred almost exclusively
during the night. His lifetime seizure frequency ranged from several
seizures a week to dozens of seizures a night and he had been
seizure-free at most for a month. He had experienced secondary
generalised tonic-clonic seizures (GTCS), which reached their peak
frequency between 21 and 23 years, when they were more than
yearly. However, GTCS had not been reported for many years before
his death. He proved to be drug-resistant for eight drugs, and at
the time of his death he was on carbamazepine 1200 mg and
topiramate 50 mg daily.
His EEGs showed very frequent interictal left fronto-centro-
temporal spikes, enhanced during sleep, and ictal rhythmic activity
in the same regions. An MRI examination disclosed a left insular-
opercular Taylor dysplasia.
A stereo-EEG study, described elsewhere [15], identiﬁed the lesion
as the site of ictal onset. Although excision of the lesion would have
had a high chance of healing his epilepsy, the risk of subsequent
language and motor deﬁcits was considered to be unacceptable, as
the lesion was in the insular region of the dominant hemisphere
and very close to the pyramidal tract.
This man died during the night, while sleeping alone. He was
found in prone. An autopsy was not performed.
4. Discussion
The incidence of SUDEP differs widely, depending mostly on the
type of epilepsy population. The lowest rates are found in inci-
dent cohorts of epilepsy (0.09 to 0.35 per 1000 person-years) [16–18]
and the highest are found in epilepsy surgery candidates or fail-
ures (6.3–9.5 per 1000 person-years) [18–20].
Sudden unexpected death in epilepsy occurs in bed at a higher
frequency than that given by chance. A review by Nobili et al. re-
ported that the mean percentage of possibly sleep-related SUDEP
in studies including more than 10 subjects was 57%, reaching 95%
in one [9].
The autonomic changes and ﬂuctuations that are peculiar to sleep
could interact with epilepsy, thus facilitating SUDEP [9]. Alterna-
tively, sleep-related circumstances such as prone position and lack
of surveillance could account for this relation. Recently, Lamberts
et al. [10] conducted a case-control study comparing people with
deﬁnite SUDEP to living controls with epilepsy. They found that
SUDEP was prominently sleep-related (58% of the events) and that
those who died were more likely to have a history of nocturnal sei-
zures than the living controls. They concluded that nocturnal seizures
might be an independent risk factor for SUDEP [10].
Surprisingly enough, the incidence rate of SUDEP in the present
population with NFLE (0.36 per 1000 person-years) was lower than
those previously reported in epilepsy clinic patients (1.08 to 5 per
1000 person-years) [21–24] and comparable to that of prevalent
Fig. 2. Frequency of seizures in the population. (A) Frequency at onset (data re-
ferred to 95 people, missing information in 8). (B) Peak frequency of seizures (101
people, 2 missing). (C) Frequency of seizures at the last observation (101 people, 2
missing).
Table 1
Demographic and clinical data of patients with <90% seizures during sleep.
N 50
Gender M 58%
F 42%
Median time from seizure onset to last observation 27 (Range 9–63)
Mean age at epilepsy onset 9 (Range 0–34)
Mean age at last observation 38 (Range 11–79)
Peak frequency of seizures Every night 86.5%
Weekly 10%
Monthly 2.5%
Unknown 1%
GTCS 48%
OSA comorbidity 4%
Therapy None 8%
Monotherapy 44%
Polytherapy 48%
Surgery candidates 30% (Operated: 8%)
234 B. Mostacci et al./Sleep Medicine 16 (2015) 232–236
populations (0.4 to 2.3 per 1000 person-years) [18,25], even con-
sidering the highest limit of the conﬁdence intervals (95% CI 0.01
to 2.0).
It is well established that GTCS are the most life-threatening kind
of seizures. The occurrence of a GTCS shortly before death is a very
frequent ﬁnding in witnessed and recorded SUDEP cases [1–7], as
are clinical signs of terminal GTCS such as tongue biting [2]. A com-
bined analysis of four case-control studies found that the presence
and frequency of GTCS was the strongest single risk factor for SUDEP
[26] and this was also conﬁrmed after assessing the type and number
of antiepileptic drugs and GTCS frequency concurrently [27]. GTCS
preceded all 16 deaths and three of the ﬁve near-deaths in the
MORTality in Epilepsy Monitoring Unit Study (MORTEMUS) series,
which was a multicentric retrospective study analyzing all SUDEP
and near-SUDEP recorded in 147 video-EEG monitoring units [8].
The present ﬁndingsmight depend on the low occurrence of GTCS
in the studied population. Despite a high frequency of focal sei-
zures, less than one third of the population experienced GTCS and
most of them had only sporadic (or unique) episodes. This is in agree-
ment with previous data showing that, although sleep has a more
pronounced promoting effect on seizures arising from the frontal
lobe than on seizures arising from other brain regions, it has a pro-
moting effect on secondary generalisation of temporal and
occipitoparietal, but not frontal seizures [28]. Even though it is es-
tablished that seizures presenting with NFLE semiology could arise
from other brain regions, the vast majority actually arise from the
frontal lobe [29].
However, Lamberts et al. found that nocturnal seizures were still
signiﬁcantly associatedwith SUDEP, even after adjusting for the pres-
ence of GTCS in a multivariate analysis [10]. Therefore, other more
elusive factors could account for this unexpected low incidence of
SUDEP in NFLE. Because peoplewith NFLEmainly have seizureswhile
sleeping, supervision at night could be greater in this population
than in epilepsies in which night seizures are occasional. Unfortu-
nately, information on night supervision was not collected; however,
this would have been diﬃcult to procure over many years of follow-
up at different ages. Prospective collection of this information could
be useful.
The man who died from SUDEP had early onset refractory
epilepsy with a high seizure frequency, all of which are ascer-
tained risk factors for SUDEP. However, it is felt that the diagnosis
should be reformulated as SUDEP Plus, according to the proposal
by Nashef et al. [14], due to the OSA comorbidity. Obstructive sleep
apnoea is thought to facilitate arrhythmias and has been proven
to be an independent risk factor for sudden death, especially at
night time [30,31]. This should be taken into account, as OSA was
found in up to 7.8% of the present population, which is in agree-
ment with previous reports of a high prevalence of OSA in people
with epilepsy, particularly in refractory cases [32–34]. In addition,
treating OSA could improve seizure control in comorbid people
[35,36].
Furthermore, this man had seizures that originated in the insula,
as demonstrated by a stereo-EEG study. Ryvlin described a similar
patient, with insular epilepsy and nocturnal hypermotor seizures,
who died from SUDEP [37]. Two further patients, recorded in video-
EEGmonitoring and described in the MORTEMUS study, had a near-
SUDEP event following an insular seizure, one of them after an
ictal asystole and the other after a postictal cardiorespiratory arrest
[8]. Thus, due to the role of this region in cardiovascular control,
seizures arising from the insula might carry a higher risk of SUDEP
[37].
The present study was restricted to people with nocturnal sei-
zures, which accounted for ≥90% of the total, in order to limit the
observation to a subpopulation of NFLE who might be at highest
risk of SUDEP, according to literature data. However, no SUDEP cases
occurred in the 62 excluded cases.
5. Conclusions
In people with NFLE, there was no higher risk of SUDEP. Accord-
ing to the present study, which was conducted on a large cohort
of patients with a rare syndrome characterised by seizures occur-
ring predominantly or exclusively during sleep, and who were
followed up for a long period, an additional factor may be re-
quired to make nocturnal seizures a risk factor for SUDEP. This could
be the occurrence of GTCS.
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